加载中...

Amgen Inc. (AMGN) 财务分析 | 估值·财报 | 100Baggers.club

Amgen Inc.

AMGN

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

加载图表中...

加载图表中...

📊 估值

关键估值指标

EV/EBITDA (TTM)

i

Enterprise Value, EBITDA and Ratio

EV/EBIT (TTM)

i

Enterprise Value, EBIT and Ratio

EV/Sales (TTM)

i

Enterprise Value, Revenue and Ratio

P/E Ratio (TTM)

i

Market Cap, Net Income and Ratio

P/B Ratio (Quarterly)

i

Market Cap, Book Value and Ratio

FCF Yield (TTM)

i

FCF, Enterprise Value and Yield

PR Profit Ratio (PPM)

i

PE Ratio, ROE and Profit Ratio (PR = PE / ROE)

📈 成长

营收、盈利和每股成长指标

Revenue (Quarterly)

i

Quarterly Revenue

Revenue/Share (Quarterly)

i

Revenue Per Share

Net Income (Quarterly)

i

Quarterly Net Income

EPS (Quarterly)

i

Earnings Per Share

Gross Profit/Share (Quarterly)

i

Gross Profit Per Share

OCF/Share (Quarterly)

i

Operating Cash Flow Per Share

FCF/Share (Quarterly)

i

Free Cash Flow Per Share

Operating Leverage (YoY)

i

Change in Operating Income / Change in Revenue

💰 盈利

利润率和净资产收益率

Gross Margin (TTM)

i

Revenue, Gross Profit and Gross Margin

Operating Margin (TTM)

i

Revenue, Operating Income and Operating Margin

Net Profit Margin (TTM)

i

Revenue, Net Income and Net Profit Margin

ROE (TTM)

i

Equity, Net Income and Return on Equity

ROA (TTM)

i

Assets, Net Income and Return on Assets

ROTCE - Return on Tangible Common Equity (TTM)

i

Net Income, Tangible Common Equity and ROTCE

OCF Margin (TTM)

i

Revenue, Operating Cash Flow and OCF Margin

FCF Margin (TTM)

i

Revenue, Free Cash Flow and FCF Margin

💵 现金质量

现金流质量和转换指标

OCF/NI Ratio (TTM)

i

Operating Cash Flow, Net Income and Ratio

FCF/NI Ratio (TTM)

i

Free Cash Flow, Net Income and Ratio

OCF/Capex (TTM)

i

Operating Cash Flow, Capex and Coverage Ratio

OCF/SBC (TTM)

i

Operating Cash Flow, SBC and Coverage Ratio

🛡️ 财务韧性

债务、流动性和财务健康度

Debt/Equity (quarterly)

i

Total Debt, Total Equity and Debt/Equity Ratio

EBITDA/Net Debt (TTM)

i

EBITDA, Net Debt and Coverage Ratio

Interest Coverage (TTM)

i

EBIT, Interest Expense and Coverage Ratio

Current Ratio (quarterly)

i

Current Assets, Current Liabilities and Current Ratio

Quick Ratio (quarterly)

i

Quick Assets, Current Liabilities and Quick Ratio

Altman Z-Score

i

Financial Distress Prediction Model

⚙️ 运营与资本效率

资产利用率、营运资本、ROIC和资本效率

ROIC (TTM)

i

NOPAT, Invested Capital and Return on Invested Capital

ROCE - Return on Capital Employed (TTM)

i

EBIT, Capital Employed and Return on Capital Employed

Asset Turnover (TTM)

i

Revenue, Total Assets and Turnover Ratio

CapEx/Depreciation - Investment Intensity (TTM)

i

CapEx, Depreciation and Ratio (>1=Expansion, <1=Contraction)

R&D/Gross Profit - R&D Intensity (TTM)

i

R&D Expenses, Gross Profit and Ratio

SG&A/Revenue - SG&A Efficiency (TTM)

i

SG&A Expenses, Revenue and Ratio

Cash Conversion Cycle (TTM)

i

DSO + DIO - DPO (in days)

DSO - Days Sales Outstanding (TTM)

i

Average Receivables and Days Sales Outstanding

DIO - Days Inventory Outstanding (TTM)

i

Average Inventory and Days Inventory Outstanding

DPO - Days Payables Outstanding (TTM)

i

Average Payables and Days Payables Outstanding

Goodwill/Assets (Quarterly)

i

Goodwill as % of Total Assets

🎁 股东回报

股息、股票回购、稀释和内部人交易活动

Dividend Yield (TTM)

i

Dividend Per Share, Share Price and Dividend Yield

Buyback Yield (TTM)

i

Net Buyback and Buyback Yield

Buyback Yield (3 Years)

i

Net Buyback 3Y and Buyback Yield 3Y

Dilution Rate (1 Year)

i

Current Shares, 1Y Ago Shares and Dilution Rate

Dilution Rate (3 Years)

i

Current Shares, 3Y Ago Shares and Dilution Rate

SBC Offset Rate (TTM)

i

Buyback / Stock-Based Comp and SBC Ratio

Insider Activity Rate (TTM)

i

Insider Net Buying and Activity Rate

利润瀑布图分析

加载图表中...

P

盈利能力指标

Gross Profit Margini毛利率

68.16%

毛利润 = $5.87B

营业收入 = $8.62B

Operating Profit Margini营业利润率

30.94%

营业利润 = $2.67B

营业收入 = $8.62B

EBITDA MarginiEBITDA利润率

31.81%

EBITDA = $2.74B

营业收入 = $8.62B

EBIT MarginiEBIT利润率

31.81%

EBIT = $2.08B

营业收入 = $8.62B

Net Profit Margini净利率

21.11%

净利润 = $1.82B

营业收入 = $8.62B

Pretax Profit Margini税前利润率

24.18%

税前利润 = $2.08B

营业收入 = $8.62B

E

运营效率指标

Interest Coveragei利息保障倍数

5.02x

EBIT (TTM) = $13.56B

利息费用 (TTM) = $2.70B

3.2x

3.5x

3.9x

4.9x

5.0x

SG&A / Revenuei销管费率

18.59%

销售及管理费用 = $1.60B

营业收入 = $8.62B

R&D / Revenuei研发占比

19.95%

研发费用 = $1.72B

营业收入 = $8.62B

R

回报率指标 (TTM)

ROAi总资产回报率

8.58%

净利润 = $7.80B

平均总资产 = $90.94B

ROEi净资产收益率

101.32%

净利润 = $7.80B

平均股东权益 = $7.70B

ROICi投入资本回报率

18.51%

NOPAT (TTM) = $10.11B

平均投入资本 = $54.63B

(NOPAT = 营业利润 × (1 - 有效税率))

(平均投入资本 = (本期IC + 去年同期IC) / 2)

Revenue Growthi营收增长率

5.76%

当期营收 = $8.62B

去年同期营收 = $8.15B

+9.4%

+9.3%

+12.4%

+8.9%

+5.8%

Operating Cash Flow/Sharei每股经营现金流

$19.77

经营现金流 = $10.76B

流通股数 = 0.54B

$22.54

$22.21

$24.22

$18.34

$19.77

综合分析

利润表项目	同比增长	当季数据	趋势
营业收入	+5.8%	$8.62B	↑
毛利	+13.4%	$5.87B, 68.16%	↑
营业利润	+126.3%	$2.67B, 30.94%	↑
EBITDA	-32.9%	$2.74B, 31.81%	↓
税前利润	+5.6%	$2.08B, 24.18%	↑
净利润	+5.1%	$1.82B, 21.11%	↑
稀释每股收益	+4.4%	3.34	↑

加载图表中...

L

流动性指标

Current Ratioi流动比率

1.26

正常

流动资产 = $31.48B

流动负债 = $24.95B

Quick Ratioi速动比率

1.01

健康

速动资产 = $25.29B

流动负债 = $24.95B

Cash Ratioi现金比率

0.48

正常

现金及等价物 = $12.04B

流动负债 = $24.95B

Cash Ratio = (Cash + Short-term Investments) / Current Liabilities

L

杠杆指标

Debt to Equityi债务权益比

6.24

关注

总债务 = $57.32B

总权益 = $9.19B

Liabilities to Assetsi资产负债率 (总负债)

90.1%

关注

总负债 = $83.31B

总资产 = $92.50B

Equity Multiplieri权益乘数

10.07

关注

总资产 = $92.50B

总权益 = $9.19B

E

效率指标

Asset Turnoveri总资产周转率

0.41

关注

营收 (TTM) = $37.24B

平均总资产 = $90.94B

Inventory Turnoveri存货周转率

1.71

关注

营业成本 (TTM) = $10.63B

平均存货 = $6.21B

Receivables Turnoveri应收账款周转率

3.98

关注

营收 (TTM) = $37.24B

平均应收账款 = $9.35B

S

偿债能力

Interest Coveragei利息保障倍数

5.02

健康

EBIT (TTM) = $13.56B

利息费用 (TTM) = $2.70B

Net Debt to EBITDAi净债务/EBITDA

2.61

正常

净债务 = $45.28B

EBITDA (TTM) = $17.34B

Debt Service Coveragei偿债覆盖率

1.98

正常

经营现金流 (TTM) = $10.76B

债务偿付 = $5.44B

V

价值指标

Goodwill %i商誉占比

20.2%

关注

商誉 = $18.67B

总资产 = $92.50B

Working Capital Ratioi营运资本比率

0.07

关注

营运资本 = $6.52B

总资产 = $92.50B

现金流瀑布图

加载图表中...

流入

流出

小计

起止点

C

现金流指标

经营现金流 TTMi

$10.76B

自由现金流 TTMi

$8.60B

FCF = OCF - CapEx

经营现金流 (TTM) = $10.76B

资本支出 (TTM) = $-2.16B

自由现金流收益率i

4.60%

关注

FCF (TTM) = $8.60B

市值 = $186.97B

经营现金流/销售比i

28.88%

健康

经营现金流 (TTM) = $10.76B

营业收入 (TTM) = $37.24B

Q

质量与覆盖指标

收益质量i

1.38x

健康

经营现金流 (TTM) = $10.76B

净利润 (TTM) = $7.80B

现金流/债务比i

0.19x

关注

经营现金流 (TTM) = $10.76B

总负债 = $57.32B

短期覆盖率i

0.43x

正常

经营现金流 (TTM) = $10.76B

流动负债 = $24.95B

资本支出覆盖率i

4.98x

健康

经营现金流 (TTM) = $10.76B

资本支出 (TTM) = $2.16B

E

效率指标

⚡ 比率按USD计算，去除汇率影响

自由/经营现金流比i

79.93%

正常

自由现金流 (TTM) = $8.60B

经营现金流 (TTM) = $10.76B

资本支出/营收比i

5.80%

正常

资本支出 (TTM) = $2.16B

营业收入 (TTM) = $37.24B

净债务/EBITDAi

2.61

正常

净债务 = $45.28B

EBITDA (TTM) = $17.34B

G

增长指标

经营现金流增长率i

57.37%

健康

当期OCF (TTM) = $2.19B

上期OCF = $1.39B

股东盈余i

$9.42B

健康

净利润 (TTM) = $7.80B

+ 折旧摊销 (TTM) = $3.78B

- 资本支出 (TTM) = $-2.16B